Company profile: Pieris Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of clinical-stage immuno-oncology biotechnology programs, including 4-1BB bispecific programs developed with Pfizer, Servier, and Boston Pharmaceuticals, and potential future partnership royalties from sales of approved partnered immuno-oncology assets.
Products and services
- Boston Pharmaceuticals-partnered 4-1BB bispecific program: Clinical-stage asset employing a 4-1BB bispecific format, developed with Boston Pharmaceuticals for immuno-oncology applications within partnered development frameworks
- Pfizer-partnered 4-1BB bispecific program: Immuno-oncology-focused program built around 4-1BB bispecific engagement, developed with Pfizer to advance partnered assets through clinical development in oncology
- Servier-partnered 4-1BB bispecific program: Bispecific-format program leveraging 4-1BB engagement, developed with Servier to progress partnered immuno-oncology assets along collaborative clinical pipelines
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Pieris Pharmaceuticals
FibroGen
HQ: United States
Website
- Description: Provider of novel therapeutics leveraging CTGF and HIF biology, including Roxadustat, an oral small molecule for anemia in CKD patients on or off dialysis; Pamrevlumab, a human monoclonal antibody in development for metastatic and locally advanced pancreatic cancer and DMD; and FG-3246, a first-in-class fully human ADC targeting CD46 for metastatic castration-resistant prostate cancer and other tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full FibroGen company profile →
Coley Pharmaceutical
HQ: United States
Website
- Description: Provider of biopharmaceutical therapeutics and drug candidates that direct the human immune system to fight cancers, asthma, allergy, and autoimmune disorders, and to enhance the effectiveness of vaccines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Coley Pharmaceutical company profile →
Sunovion
HQ: United States
Website
- Description: Provider of therapeutic products discovered, developed and commercialized for central nervous system and respiratory disorders and other illnesses. Portfolio includes Latuda for schizophrenia and bipolar depression; Aptiom for partial-onset seizures; Gemtesa/vibegron for overactive bladder; Myfembree for heavy menstrual bleeding due to uterine fibroids; Orgovyx for advanced prostate cancer; LUNESTA; and XOPENEX.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sunovion company profile →
Valeo Pharma
HQ: Canada
Website
- Description: Provider of specialty pharmaceutical products and healthcare solutions, focused on commercializing innovative prescription therapies that address the needs of patients with complicated or rare diseases, serving healthcare professionals and patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Valeo Pharma company profile →
PD-Rx Pharmaceuticals
HQ: United States
Website
- Description: Provider of quality products and personal customer service to the healthcare industry.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PD-Rx Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Pieris Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Pieris Pharmaceuticals
2.2 - Growth funds investing in similar companies to Pieris Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Pieris Pharmaceuticals
4.2 - Public trading comparable groups for Pieris Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →